Published in Mycoses on January 01, 2006
Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother (2008) 3.12
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. J Antimicrob Chemother (2013) 1.63
Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother (2012) 1.39
Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother (2009) 1.24
Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience. Haematologica (2011) 1.17
Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob Agents Chemother (2009) 0.90
Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother (2010) 0.89
Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis (2012) 0.83
Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing. Antimicrob Agents Chemother (2010) 0.81
Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol (2012) 0.79
Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob Agents Chemother (2013) 0.76
Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med (2004) 8.11
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet (2007) 3.11
Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood (2005) 2.97
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs (2007) 2.09
Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica (2010) 1.91
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy (2008) 1.79
Patients at high risk of invasive fungal infections: when and how to treat. Drugs (2008) 1.62
Central venous catheter (CVC)-related infections in neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 1.62
Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis (2006) 1.54
Primary antifungal prophylaxis in acute myeloblastic leukemia and myelodysplastic syndrome--still an open question? Leuk Lymphoma (2010) 1.40
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis (2012) 1.39
Therapy of the neonatal abstinence syndrome with tincture of opium or morphine drops. Drug Alcohol Depend (2005) 1.21
Treatment of invasive fungal infections in cancer patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2008) 1.17
Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol (2003) 1.15
Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol (2012) 1.15
Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer (2009) 1.13
Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Ann Hematol (2004) 1.08
Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother (2010) 1.07
Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy (2011) 1.07
Posaconazole concentrations in the central nervous system. J Antimicrob Chemother (2008) 1.06
Invasive candidiasis and candidemia: from current opinions to future perspectives. Expert Opin Investig Drugs (2009) 1.03
Fungal endocarditis. Curr Opin Infect Dis (2013) 1.00
Efficacy of caspofungin and itraconazole as secondary antifungal prophylaxis: analysis of data from a multinational case registry. Int J Antimicrob Agents (2009) 0.98
Intracellular concentrations of posaconazole in different compartments of peripheral blood. Antimicrob Agents Chemother (2010) 0.97
A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect (2007) 0.97
Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2013) 0.96
Our 2014 approach to mucormycosis. Mycoses (2014) 0.96
PTX3 deficiency and aspergillosis. N Engl J Med (2014) 0.96
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica (2013) 0.93
Posaconazole: a next-generation triazole antifungal. Future Microbiol (2007) 0.93
Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis (2008) 0.92
Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother (2011) 0.91
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol (2013) 0.90
Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother (2010) 0.89
Voriconazole brain tissue levels in rhinocerebral aspergillosis in a successfully treated young woman. Int J Antimicrob Agents (2006) 0.89
Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother (2009) 0.88
Aspergillus PCR testing: results from a prospective PCR study within the AmBiLoad trial. Eur J Haematol (2010) 0.87
Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol (2008) 0.87
Diagnosis and treatment of documented infections in neutropenic patients--recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol (2003) 0.86
Antifungal treatment strategies in high risk patients. Mycoses (2008) 0.85
Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice. Future Microbiol (2006) 0.85
Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis. Antimicrob Agents Chemother (2013) 0.85
Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany. Value Health (2006) 0.84
Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital setting. Ann Hematol (2007) 0.84
Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses (2011) 0.83
Anidulafungin--state of affairs from a clinical perspective. Mycoses (2007) 0.82
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial. Br J Haematol (2005) 0.82
Efficacy and safety of moxifloxacin as antibacterial prophylaxis for patients receiving autologous haematopoietic stem cell transplantation: a randomised trial. Int J Antimicrob Agents (2011) 0.81
Voriconazole versus liposomal amphotericin B for empirical antifungal therapy. N Engl J Med (2002) 0.81
Population pharmacokinetic analysis of circadian rhythms in hepatic CYP3A activity using midazolam. J Clin Pharmacol (2014) 0.80
Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression. Curr HIV Res (2008) 0.80
Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients. Mycoses (2011) 0.80
Aspergillosis of bones and joints - a review from 2002 until today. Mycoses (2014) 0.80
Voriconazole as secondary antifungal prophylaxis in stem cell transplant recipients. Haematologica (2011) 0.80
Our 2014 approach to candidaemia. Mycoses (2014) 0.80
Antifungal prophylaxis for invasive mycoses in high risk patients. Curr Opin Infect Dis (2006) 0.80
Zygomycosis--current epidemiological aspects. Mycoses (2007) 0.79
Intracellular concentrations of micafungin in different cellular compartments of the peripheral blood. Int J Antimicrob Agents (2012) 0.79
The effect of mitomycin C in reducing epidural fibrosis after lumbar laminectomy in rats. J Neurosurg Spine (2006) 0.78
Fungus-specific CD4(+) T cells for rapid identification of invasive pulmonary mold infection. Am J Respir Crit Care Med (2015) 0.78
Development of new strategies for early diagnosis of mucormycosis from bench to bedside. Mycoses (2014) 0.78
Salvage therapy of refractory chronic disseminated candidiasis in a patient with acute myeloid leukaemia and secondary prophylaxis during allogeneic stem cell transplantation. Mycoses (2006) 0.78
Intracellular concentrations of anidulafungin in different compartments of the peripheral blood. Int J Antimicrob Agents (2013) 0.78
Treatment options in candidaemia. Mycoses (2007) 0.78
Treatment of invasive candidiasis with echinocandins. Mycoses (2009) 0.78
Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis. Mycoses (2013) 0.78
Association of HSV reactivation and pro-inflammatory cytokine levels with the severity of stomatitis after BEAM chemotherapy and autologous SCT. Support Care Cancer (2010) 0.78
Prospective evaluation of the pharmacodynamics of piritramide in neonates and infants. Eur J Pediatr (2007) 0.77
Disseminated Fusariosis in Immunocompromised Children - Analysis of Recent Cases Identified in the Global FungiScope Registry. Pediatr Infect Dis J (2016) 0.77
Combined intra- and extracranial cryptococcal infection of a 20-year-old patient in right temporal area. J Oral Maxillofac Surg (2010) 0.76
Choosing a study population for the evaluation of antifungal prophylaxis. Clin Infect Dis (2005) 0.76
Treatment of invasive fungal infections in clinical practice: a multi-centre survey on customary dosing, treatment indications, efficacy and safety of voriconazole. Int J Hematol (2008) 0.76
Pharmacokinetics of piritramide in newborns, infants and young children in intensive care units. Eur J Pediatr (2006) 0.75
Itraconazole versus fluconazole for antifungal prophylaxis. Ann Intern Med (2004) 0.75
Current controversies in treating invasive zygomycosis. J Pediatr Hematol Oncol (2010) 0.75
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother (2016) 0.75
Comment on: Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother (2005) 0.75
Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother (2017) 0.75
[Zygomycosis after hematogeneic stem cell transplantation--a current problem?]. Med Klin (Munich) (2006) 0.75
[Vaccination of the immunocompromised host]. Wien Med Wochenschr (2004) 0.75
[Current development in the diagnostics and therapy of systemic fungal infections in cancer patients]. Wien Med Wochenschr (2004) 0.75
Second-line treatment in invasive mould infections. Mycoses (2006) 0.75
Surgical site infections: current management and role of new antibiotics. Curr Opin Infect Dis (2019) 0.75
Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis (2006) 0.75
Anidulafungin: advantage for the newcomer? Expert Rev Clin Pharmacol (2008) 0.75
Diagnosis and treatment of fungal infections in allogeneic stem cell and solid organ transplant recipients. Expert Opin Pharmacother (2010) 0.75
Ovarian cancer treatment reality in northern Rheinland-Pfalz (Germany). Suboptimal surgical treatment as a possible cause for inferior survival. Onkologie (2007) 0.75
[Echinocandins in invasive candidiasis]. Med Klin (Munich) (2008) 0.75
Physiology-based pharmacokinetics of caspofungin for adults and paediatrics. Pharm Res (2014) 0.75